nach oben

Erschienen in:

05.12.2019 | Main topic

Biomarkers in primary prevention

Meaningful diagnosis based on biomarker scores?

verfasst von: Christian Schulte, MD, Tanja Zeller, PhD

Erschienen in: Herz | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Cardiovascular (CV) risk assessment is based on the utilization of risk scores, enabling clinicians to estimate an individual’s risk to develop CV pathologies and events. Such risk scores comprise classic CV risk factors such as smoking, diabetes, hypertension, and blood cholesterol levels. Recently, other CV biomarkers such as cardiac troponins have been suggested and evaluated as alternative biomarkers not only in the acute diagnostic setting of myocardial infarction, but also as markers for risk stratification in the general population. In this review, we summarize the current knowledge on biomarkers in the field of primary prevention in cardiovascular disease (CVD). Furthermore, we present potential alternative biomarker-based strategies for CV risk assessment. In this respect we provide an outlook on the potential use of genomic variation as well as circulating non-coding RNAs to complement current risk assessment strategies so as to further personalize risk stratification in CVD.

World Health Organization http://www.emro.who.int/about-who/public-health-functions/health-promotion-disease-prevention.html. Accessed: 1 Nov 2019

Kannel WB, Dawber TR, Kagan A et al (1961) Factors of risk in the development of coronary heart disease—six-year follow-up experience. Ann Intern Med 55:33. https://doi.org/10.7326/0003-4819-55-1-33 CrossRefPubMed

Arnett DK, Blumenthal RS, Albert MA et al (2019) 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140:e596–e646. https://doi.org/10.1161/CIR.0000000000000678 CrossRefPubMedPubMedCentral

Piepoli MF, Hoes AW, Agewall S et al (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 37:2315–2381. https://doi.org/10.1093/eurheartj/ehw106 CrossRefPubMedPubMedCentral

Pencina MJ, Navar AM, Wojdyla D et al (2019) Quantifying importance of major risk factors for coronary heart disease. Circulation 139:1603–1611. https://doi.org/10.1161/CIRCULATIONAHA.117.031855 CrossRefPubMed

Graham I, Shear C, De Graeff P et al (2018) New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. Eur Heart J Cardiovasc Pharmacother 4:119–127. https://doi.org/10.1093/ehjcvp/pvx031 CrossRefPubMed

McNeil JJ, Wolfe R, Woods RL et al (2018) Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 379:1509–1518. https://doi.org/10.1056/NEJMoa1805819 CrossRefPubMedPubMedCentral

Group BDW (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95. https://doi.org/10.1067/mcp.2001.113989 CrossRef

D’Agostino RB, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care. Circulation 117:743–753. https://doi.org/10.1161/CIRCULATIONAHA.107.699579 CrossRefPubMed

10.

Authors/Task Force Members MF, Piepoli MF, Hoes AW et al (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 23:NP1–NP96. https://doi.org/10.1177/2047487316653709 CrossRef

11.

Thygesen K, Alpert JS, Jaffe AS et al (2012) Third universal definition of myocardial infarction. J Am Coll Cardiol 60:1581–1598. https://doi.org/10.1016/J.JACC.2012.08.001 CrossRefPubMed

12.

Roffi M, Patrono C, Collet J‑P et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 37:267–315. https://doi.org/10.1093/eurheartj/ehv320 CrossRefPubMed

13.

Aengevaeren VL, Hopman MTE, Thompson PD et al (2019) Exercise-induced cardiac Troponin I increase and incident mortality and cardiovascular events. Circulation 140:804–814. https://doi.org/10.1161/CIRCULATIONAHA.119.041627 CrossRefPubMed

14.

Blankenberg S, Salomaa V, Makarova N et al (2016) Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. Eur Heart J 37:2428–2437. https://doi.org/10.1093/eurheartj/ehw172 CrossRefPubMedPubMedCentral

15.

Ford I, Shah ASV, Zhang R et al (2016) High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J Am Coll Cardiol 68:2719–2728. https://doi.org/10.1016/j.jacc.2016.10.020 CrossRefPubMedPubMedCentral

16.

Neumann JT, Twerenbold R, Ojeda F et al (2019) Application of high-sensitivity troponin in suspected myocardial infarction. N Engl J Med 380:2529–2540. https://doi.org/10.1056/NEJMoa1803377 CrossRefPubMed

17.

Sigurdardottir FD, Lyngbakken MN, Holmen OL et al (2018) Relative prognostic value of cardiac Troponin I and C‑reactive protein in the general population (from the Nord-Trøndelag health [HUNT] study). Am J Cardiol 121:949–955. https://doi.org/10.1016/j.amjcard.2018.01.004 CrossRefPubMed

18.

Blankenberg S, Zeller T, Saarela O et al (2010) Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 121:2388–2397. https://doi.org/10.1161/CIRCULATIONAHA.109.901413 CrossRefPubMed

19.

Ganz P, Heidecker B, Hveem K et al (2016) Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA 315:2532. https://doi.org/10.1001/jama.2016.5951 CrossRefPubMed

20.

Jacquet S, Yin X, Sicard P et al (2009) Identification of cardiac myosin-binding protein C as a candidate biomarker of myocardial infarction by proteomics analysis. Mol Cell Proteomics 8:2687–2699. https://doi.org/10.1074/mcp.M900176-MCP200 CrossRefPubMedPubMedCentral

21.

Marjot J, Kaier TE, Martin ED et al (2017) Quantifying the release of biomarkers of myocardial necrosis from cardiac myocytes and intact myocardium. Clin Chem 63:990–996. https://doi.org/10.1373/clinchem.2016.264648 CrossRefPubMedPubMedCentral

22.

Kaier TE, Twerenbold R, Puelacher C et al (2017) Direct comparison of cardiac myosin-binding protein C with cardiac troponins for the early diagnosis of acute myocardial infarction. Circulation 136:1495–1508. https://doi.org/10.1161/CIRCULATIONAHA.117.028084 CrossRefPubMedPubMedCentral

23.

Baker JO, Tyther R, Liebetrau C et al (2015) Cardiac myosin-binding protein C: a potential early biomarker of myocardial injury. Basic Res Cardiol 110:23. https://doi.org/10.1007/s00395-015-0478-5 CrossRefPubMedPubMedCentral

24.

Schulte C, Barwari T, Joshi A et al (2019) Comparative analysis of circulating noncoding RNas versus protein biomarkers in the detection of myocardial injury. Circ Res 125:328–340. https://doi.org/10.1161/CIRCRESAHA.119.314937 CrossRefPubMedPubMedCentral

25.

Anand A, Chin C, Shah ASV et al (2018) Cardiac myosin-binding protein C is a novel marker of myocardial injury and fibrosis in aortic stenosis. Heart 104:1101–1108. https://doi.org/10.1136/heartjnl-2017-312257 CrossRefPubMed

26.

Erdmann J, Kessler T, Munoz Venegas L, Schunkert H (2018) A decade of genome-wide association studies for coronary artery disease: the challenges ahead. Cardiovasc Res 114:1241–1257. https://doi.org/10.1093/cvr/cvy084 CrossRefPubMed

27.

Holdt LM, Stahringer A, Sass K et al (2016) Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun 7:12429. https://doi.org/10.1038/ncomms12429 CrossRefPubMedPubMedCentral

28.

Tikkanen E, Havulinna AS, Palotie A et al (2013) Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol 33:2261–2266. https://doi.org/10.1161/ATVBAHA.112.301120 CrossRefPubMedPubMedCentral

29.

Ganna A, Magnusson PKE, Pedersen NL et al (2013) Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler Thromb Vasc Biol 33:2267–2272. https://doi.org/10.1161/ATVBAHA.113.301218 CrossRefPubMed

30.

Rao AS, Knowles JW (2019) Polygenic risk scores in coronary artery disease. Curr Opin Cardiol 34:435–440. https://doi.org/10.1097/HCO.0000000000000629 CrossRefPubMed

31.

Khera AV, Chaffin M, Aragam KG et al (2018) Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 50:1219–1224. https://doi.org/10.1038/s41588-018-0183-z CrossRefPubMedPubMedCentral

32.

Inouye M, Abraham G, Nelson CP et al (2018) Genomic risk prediction of coronary artery disease in 480,000 adults. J Am Coll Cardiol 72:1883–1893. https://doi.org/10.1016/j.jacc.2018.07.079 CrossRefPubMedPubMedCentral

33.

Natarajan P, Young R, Stitziel NO et al (2017) Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from Statin therapy in the primary prevention setting. Circulation 135:2091–2101. https://doi.org/10.1161/CIRCULATIONAHA.116.024436 CrossRefPubMedPubMedCentral

34.

Clancy S, Brown W (2008) Translation: DNA to mRNA to Protein. Nat Educ 1(1):101

35.

Venter JC, Adams MD, Myers EW et al (2001) The sequence of the human genome. Science 80(291):1304–1351. https://doi.org/10.1126/science.1058040 CrossRef

36.

Ransohoff JD, Wei Y, Khavari PA (2018) The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol 19:143–157. https://doi.org/10.1038/nrm.2017.104 CrossRefPubMed

37.

Williamson L, Saponaro M, Boeing S et al (2017) UV irradiation induces a non-coding RNA that functionally opposes the protein encoded by the same gene. Cell 168:843–855.e13. https://doi.org/10.1016/J.CELL.2017.01.019 CrossRefPubMedPubMedCentral

38.

ES, Costa MC, Kurc S et al (2018) The circulating non-coding RNA landscape for biomarker research: lessons and prospects from cardiovascular diseases. Acta Pharmacol Sin 39:1085–1099. https://doi.org/10.1038/aps.2018.35 CrossRef

39.

Condorelli G, Latronico MVG, Cavarretta E (2014) microRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol 63:2177–2187. https://doi.org/10.1016/j.jacc.2014.01.050 CrossRefPubMed

40.

Arroyo JD, Chevillet JR, Kroh EM et al (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 108:5003–5008. https://doi.org/10.1073/pnas.1019055108 CrossRefPubMedPubMedCentral

41.

Vickers KC, Palmisano BT, Shoucri BM et al (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13:423–433. https://doi.org/10.1038/ncb2210 CrossRefPubMedPubMedCentral

42.

Turchinovich A, Weiz L, Langheinz A, Burwinkel B (2011) Characterization of extracellular circulating microRNA. Nucleic Acids Res 39:7223–7233. https://doi.org/10.1093/nar/gkr254 CrossRefPubMedPubMedCentral

43.

Zampetaki A, Willeit P, Tilling L et al (2012) Prospective study on circulating microRNas and risk of myocardial infarction. J Am Coll Cardiol 60:290–299. https://doi.org/10.1016/J.JACC.2012.03.056 CrossRefPubMed

44.

Jansen F, Yang X, Proebsting S et al (2014) MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. J Am Heart Assoc 3:e1249. https://doi.org/10.1161/JAHA.114.001249 CrossRefPubMedPubMedCentral

45.

Schulte C, Molz S, Appelbaum S et al (2015) miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease. PLoS ONE 10:e145930. https://doi.org/10.1371/journal.pone.0145930 CrossRefPubMedPubMedCentral

46.

Bye A, Røsjø H, Nauman J et al (2016) Circulating microRNAs predict future fatal myocardial infarction in healthy individuals—The HUNT study. J Mol Cell Cardiol 97:162–168. https://doi.org/10.1016/j.yjmcc.2016.05.009 CrossRefPubMed

47.

van Rooij E, Marshall WS, Olson EN (2008) Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 103:919–928. https://doi.org/10.1161/CIRCRESAHA.108.183426 CrossRefPubMedPubMedCentral

48.

Schulte C, Westermann D, Blankenberg S, Zeller T (2015) Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction. World J Cardiol 7:843–860. https://doi.org/10.4330/wjc.v7.i12.843 CrossRefPubMedPubMedCentral

49.

Schulte C, Zeller T (2015) microRNA-based diagnostics and therapy in cardiovascular disease-Summing up the facts. Cardiovasc Diagn Ther 5:17–36. https://doi.org/10.3978/j.issn.2223-3652.2014.12.03 CrossRefPubMedPubMedCentral

50.

Viereck J, Thum T (2017) Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury. Circ Res 120:381–399. https://doi.org/10.1161/CIRCRESAHA.116.308434 CrossRefPubMed

Titel: Biomarkers in primary prevention
Meaningful diagnosis based on biomarker scores?
verfasst von: Christian Schulte, MD
Tanja Zeller, PhD
Publikationsdatum: 05.12.2019
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 1/2020
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-019-04874-2

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Sinnvolle Diagnostik: Bildgebung

Endothelial dysfunction following coronary artery bypass grafting

Prävention kardiovaskulärer Erkrankungen: Empfehlungen zum Lebensstil

Comparison of procedural success between two radial sheaths